Literature DB >> 10102468

Vitamin K intake and sensitivity to warfarin in patients consuming regular diets.

A Lubetsky1, E Dekel-Stern, A Chetrit, F Lubin, H Halkin.   

Abstract

The effect of dietary vitamin K intake on warfarin sensitivity is known only from case reports and few small clinical studies. We followed 50 patients commencing warfarin and consuming their regular diets (for 8 weeks) to study this relationship. A one-week recall dietary questionnaire was completed at weeks 2 and 8. Daily intake of nutrients and vitamin K was calculated from standard tables. Warfarin sensitivity index (WSI) was defined as final INR/final warfarin dose (mg/day/m2 of body surface area) (week 8). Vitamin K intake was 17-974 (median: 179) microg/day. Median WSI was 0.82 (0.31-4.47). A WSI value of 1.1 significantly separated excess (>250 microg/day) from normal (<250 microg/day) vitamin K consumers (16/18 vs. 15/32, respectively, p <0.01). The former had lower day 5 INR (median: 1.9 vs. 3.0, p <0.001), needed more warfarin to achieve INR > or =2.0 (32.0+/-9.2 mg vs. 25.4+/-6.4 mg, p = 0.009) and required a higher maintenance steady state warfarin dose (5.7+/-1.7 mg/day vs. 3.5+/-1.0 mg/day, p <0.001). We conclude that in 32% (16/50) of anticoagulated patients under usual dietary conditions sensitivity to warfarin is decreased by vitamin K intake > or =250 microg/day.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10102468

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  20 in total

1.  The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.

Authors:  M A Perera; E Gamazon; L H Cavallari; S R Patel; S Poindexter; R A Kittles; D Nicolae; N J Cox
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

Review 2.  The future prospects of pharmacogenetics in oral anticoagulation therapy.

Authors:  Farhad Kamali; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

3.  Ezetimibe enhances and stabilizes anticoagulant effect of warfarin.

Authors:  Takehiro Hashikata; Minako Yamaoka-Tojo; Ryota Kakizaki; Teruyoshi Nemoto; Kazuhiro Fujiyoshi; Sayaka Namba; Lisa Kitasato; Takuya Hashimoto; Shunsuke Ishii; Ryo Kameda; Takao Shimohama; Taiki Tojo; Junya Ako
Journal:  Heart Vessels       Date:  2016-04-06       Impact factor: 2.037

4.  High intra- and inter-individual variability of plasma vitamin K concentrations in patients with atrial fibrillation under warfarin therapy.

Authors:  Y-E Kim; H I Woo; Y K On; J S Kim; S-Y Lee
Journal:  Eur J Clin Nutr       Date:  2015-04-01       Impact factor: 4.016

5.  Vitamin K intake, body mass index and warfarin maintenance dose.

Authors:  Edmond K Kabagambe; T Mark Beasley; Nita A Limdi
Journal:  Cardiology       Date:  2013-09-19       Impact factor: 1.869

6.  Apolipoprotein E (APOE) and warfarin dosing in an Italian population.

Authors:  Hugo Kohnke; Maria Gabriella Scordo; Vittorio Pengo; Roberto Padrini; Mia Wadelius
Journal:  Eur J Clin Pharmacol       Date:  2005-08-26       Impact factor: 2.953

7.  Warfarin dose related to apolipoprotein E (APOE) genotype.

Authors:  Hugo Kohnke; Kristina Sörlin; Göran Granath; Mia Wadelius
Journal:  Eur J Clin Pharmacol       Date:  2005-06-11       Impact factor: 2.953

8.  Predictors of unstable anticoagulation in African Americans.

Authors:  Larisa H Cavallari; Jonathan L Aston; Kathryn M Momary; Nancy L Shapiro; Shitalben R Patel; Edith A Nutescu
Journal:  J Thromb Thrombolysis       Date:  2008-06-19       Impact factor: 2.300

9.  Resistance to oral vitamin K for reversal of overanticoagulation during Crohn's disease relapse.

Authors:  Susan Elaine Fugate; April Michelle Ramsey
Journal:  J Thromb Thrombolysis       Date:  2004-06       Impact factor: 2.300

Review 10.  Pharmacogenetics of oral anticoagulants: a basis for dose individualization.

Authors:  Simone Stehle; Julia Kirchheiner; Andreas Lazar; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.